Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen
Top
Gepubliceerd in:

2015 | OriginalPaper | Hoofdstuk

1. Inleiding: definitie en epidemiologie

Auteur : dr. Frans Rutten

Gepubliceerd in: Zorg rondom hartfalen

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

Hartfalen komt bij 1–2 % van de algehele bevolking voor. De prevalentie neemt sterk toe met de leeftijd en ligt beduidend hoger bij risicogroepen zoals patiënten met diabetes mellitus type 2 en chronisch obstructief longlijden (COPD). De incidentie van hartfalen neemt sinds de jaren tachtig van de vorige eeuw toe, waarbij het laatste decennium het aandeel van hartfalen met verminderde ejectiefractie wat is gedaald en dat van hartfalen met behouden ejectiefractie is gestegen. De belangrijkste risicofactoren voor hartfalen zijn hypertensie en coronaire hartziekte (weer beïnvloed door traditionele risicofactoren als roken, overgewicht, hypercholesterolemie en diabetes mellitus). Daarnaast kunnen klepvitia, cardiomyopathieën, congenitale hartziekte, aritmieën (vooral atriumfibrilleren), pericardiale ziekten, myocarditis, pulmonale ziekten zoals COPD, nierfalen en cardiotoxische stoffen zoals alcohol hartfalen veroorzaken.
volgende hoofdstuk Etiologie en pathofysiologie van hartfalen
Literatuur
1.
Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068–72.PubMedCrossRef
2.
Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–13.PubMedCrossRef
3.
McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14(8):803–69.PubMedCrossRef
4.
5.
6.
Gandhi SK, Powers JC, Nomeir AM, et al. The pathogenesis of acute pulmonary edema associated with hypertension. N Engl J Med. 2001;344:17–22.PubMedCrossRef
7.
Martínez-Sellés M, Doughty RN, Poppe K, et al.; Meta-Analysis Global Group In Chronic Heart Failure (MAGGIC). Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis. Eur J Heart Fail. 2012;14:473–9.PubMedCrossRef
8.
Bursi F, Weston SA, Redfield M, et al. Systolic and diastolic heart failure in the community. JAMA. 2006;296:2209–16.PubMedCrossRef
9.
Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J. 2007;28:2539–50.PubMedCrossRef
10.
Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.PubMedCrossRef
11.
McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 1997;350:829–33.PubMedCrossRef
12.
Redfield MM, Jacobsen SJ, Burnett jr JC, et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.PubMedCrossRef
13.
Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108:977–82.PubMedCrossRef
14.
Anonymous. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992;327:685–91.CrossRef
15.
Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–9.PubMedCrossRef
16.
Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9.PubMedCrossRef
17.
Ceia F, Fronseca C, Mota T, et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002;4531–9.
18.
Owen TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47:320–32.CrossRef
19.
Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J. 2004;25:1614–9.PubMedCrossRef
20.
Rutten FH, Cramer MJ, Grobbee DE, et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26:1887–94.PubMedCrossRef
21.
Boonman-de Winter LJ, Rutten FH, Cramer MJ, et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012;55:2154–62.PubMedCentralPubMedCrossRef
22.
Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107–15.PubMedCrossRef
23.
24.
Jaarsveld CH van, Ranchor AV, Kempen GI, et al. Epidemiology of heart failure in a community-based study of subjects aged 57 years or over: incidence and long-term survival. Eur J Heart Fail. 2006;8:23–30.PubMedCrossRef
25.
Mehta PA, Dubrey SW, McIntyre HF, et al. Improving survival in the 6 months after diagnosing heart failure in the past decade: population-based data from the UK. Heart. 2009;95(22):1851–6.PubMedCrossRef
26.
Shafazand M, Schaufelberger M, Lappas G, et al. Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987–2003 from the Swedish Hospital Discharge Registry. Eur Heart J. 2009;30(6):671–8.PubMedCrossRef
27.
Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation. 2009;119(4):515–23.PubMedCrossRef
28.
Rutten FH, Heddema WS, Daggelders GJA, et al. Primary care patients with heart failure in the last year of their life. Fam Pract. 2012;29:36–42.PubMedCrossRef
29.
30.
Cox B, Vangronsveld J, Nawrot TS. Impact of stepwise introduction of smoke-free legislation on population rates of acute myocardial infarction deaths in Flanders, Belgium. Heart. 2014;100(18):1430–5.PubMedCrossRef
31.
Meyers DG, Neuberger JS, He J. Cardiovascular effect of bans on smoking in public places: a systematic review and meta-analysis. J Am Coll Cardiol. 2009;54(14);1249–55.PubMedCrossRef
32.
Lam CS, Donal E, Kraigher-Krainer E, et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:18–28.PubMedCentralPubMedCrossRef
33.
Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014;35(4):2797–815.PubMedCrossRef
34.
Reitsma JB, Mosterd A, de Craen AJ, et al. Increase in hospital admission rates for heart failure in The Netherlands, 1980–1993. Heart. 1996;76:388–92.PubMedCentralPubMedCrossRef
35.
Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J. 1997;18:208–25.PubMedCrossRef
36.
Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739–45.PubMedCrossRef
37.
Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The save Investigators. N Engl J Med. 1992;327:669–77.PubMedCrossRef
38.
Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (trace) Study Group. N Engl J Med. 1995;333:1670–6.PubMedCrossRef
Metagegevens
Titel
Inleiding: definitie en epidemiologie
Auteur
dr. Frans Rutten
Copyright
2015
Uitgeverij
Bohn Stafleu van Loghum
Boek
Zorg rondom hartfalen

Print ISBN: 978-90-368-0658-9

Elektronisch ISBN: 978-90-368-0659-6

Copyright: 2015

DOI
https://doi.org/10.1007/978-90-368-0659-6_1